Project Grant R21AI188191
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$233K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,872,722 over approximately 4 years to the University of South Florida to conduct research on Clostridioides difficile (C. difficile) infection. The research aims to elucidate the roles of penicillin-binding proteins (PBPs) and other peptidoglycan transpeptidases in C. difficile's life cycle and antibiotic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $136,104 to Tufts University School of Medicine to conduct research on the impact of Clostridioides difficile's spatial distribution and toxin gene expression on disease severity. The researchers aim to use fluorescent reporter strains to visualize C. difficile cells and their toxin gene expression during murine...
This $780,162 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Old Dominion University from August 2022 through July 2026 exploring the role of nutrient and stress sensing in regulating Clostridioides difficile physiology and behavior within the host. The research aims to determine how the stringent response regulates disease-relevant bacterial processes and characterize enzymes that mediate alarmone metabolism...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $521,030.00 to the University of North Carolina at Chapel Hill to conduct research on the role of phenotypic heterogeneity in the fitness of Clostridioides difficile, a leading cause of antibiotic-associated disease. The goal is to define the interplay between stochastic and regulatory mechanisms underlying the...
The federal Project Grant award R01AI178776 was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The $1,541,024 grant awarded to the University of Notre Dame DU Lac aims to elucidate the spore germination pathway of Clostridioides difficile and develop pharmacological interventions to inhibit spore germination, which is a key driver of recurrent C. difficile infections (CDI). The research project...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This $894,552 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at the University of Nevada, Las Vegas to probe the effect of a high-fat/high-protein diet on Clostridioides difficile infection. Specifically, the researchers will examine how such a diet impacts inflammation, intestinal permeability, and the gut microbiome before and after antibiotic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $511,553 to the University of Maryland, Baltimore to develop a novel probiotic yeast-based immunotherapy that can prevent the transmission of Clostridioides difficile (C. difficile) infections. The research aims to identify and screen lead bi-specific antibody fragments targeting the C. difficile surface protein CWP84,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,875 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arizona to advance a platform technology for Clostridioides difficile infection (CDI) treatment using antisense oligonucleotides (ASOs). The key products and services to be delivered under this 2-year grant include: In vitro studies to evaluate the minimum inhibitory concentration (MIC) and resistance...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $754,446 to the University of Tennessee Health Science Center to develop novel microbiome-sparing antibacterial treatments for Clostridioides difficile infection (CDI). The key objectives are to: 1) optimize lead inhibitor compounds targeting the bacterial enzyme FABK to improve antimicrobial potency;...